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The ability of antiby~ertensive treat 
sion of left ventricular hypertro~hy w 
various models of experi 
of different drugs were successively dis- 
wever, all these drugs do not induce the 
ventricular hypertrophy regression, and 
the effectiveness of angiotensin-converting enzyme inhibi- 
tors contrasts with the ficial effect induced 
by direct a~er~a~ vaso se~~e~t~y, it was 
concluded that factors other tkan the reduction of blood 
pressure might also influence the evolution of left ventricular 
hypertrophy and that the sympathetic nervous ystem. and 
the renin-angiotensin ystem might directly facilitate the 
development or persistence of this disease, despite the 
beneficial effects of the decrease inbloo 
For the double-blind, randomized, 6 month study re- 
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01990 by the American College of Cardiology 
orted here, we selec 
ypertension and, tke e1 severe left ventricular hyper- 
pared captopril, the drug that reduced left 
ventricular hypertrophy imal models most effectively 
(I 1,12), with minoxid% 
tion of all the drugs test 
ients were selected according to spe- 
male outpatients, aged 30 to 65 years, 
with essential resistant hypertension. Resist 
was defined by I) diastolic blood pressure >
IO min in the supine position at the outpati 
mglday of met~pro~ol and 80 
diastolic biood pressure 
t inpatient eva~nat~on on 
treatment. All patients gave their informed consent for 
participating in this study and agreed to a con twice 
a month for 6 months that included 72 h of eval- 
uations. Patients with at least one of the following cri- 
teria were excluded: uncontrolled heart failure, high degree 
atrioventricular block, kidney failure (seturn creatinine >Z!oO 
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WoYliter), uncontrolled angina pectoris, myocardial infarc- 
tion, other severe disease or probable poor compliance with 
therapy. 
Study protocol. After initial selection all patients were 
hospitalized toexclude the possibility of secondary hyper- 
tension and to assess their resistance to therapy. Patients 
were then randomly allocated to treatment with either mi- 
noxidil or captopril n addition to the 200 mglday of meto- 
pro101 and 80 mg of furosemide they were already taking. 
Captopril and minoxidil were given three times a day as 
capsules with the same appearance and were provided by 
Squibb and Upjohn, respectively. The initial dose of capto- 
pril was 75 mg, which was progressively increased to 150, 
225 or 300 mg until the diastolic blood pressure goal of < 100 
mm Hg was reached. The initial dose of minoxidil was 7.5 
mg, which was progressively increased to 15, 22.5 or 30 
mg/day if necessary, until the diastolic blood pressure goal 
was reached. At first, patients were seen every 2 weeks at 
the outpatient clinic. Once diastolic blood pressure was 
C 100 mm Hg, they were seen monthly. A second evaluation 
was performed atthe end of the 6th month of treatment. 
When necessary, diuretic therapy could be altered 
throughout the study us follows: 1) the furosemide dosage 
could be increased incases of edema or poor blood pressure 
control, or both, when patients were given the maximal 
regimen of either captopril or minoxidil; and 2) if serum 
potassium levels fell to <3.5 mmoyliter, 50 to 100 mg/day of 
spironolactone could also be added to the drug regimen. 
Methods of Evaluation 
pressure. Blood pressure and heart rate were mea- 
su to 3 h after drug intake. After a 20 min rest, supine 
blood pressure was measured with a standard mercury 
sphygmomanometer. Blood pressure and heart rate were 
again measured after 2 min in the upright position. All blood 
pressure measurements were performed by the same physi- 
cian (M.A.D.). Phase V of the Korotkov sounds was taken 
as the diastolic blood pressure. 
eft ventricular hypertrophy. Echocardiography was 
performed before randomization a d at the end of the 6 
month study period. Echocardiograms were recorded after a 
15 min rest in the supine position, on a sectorial device (ATL 
Mark 300) with a strip chart recorder (paper speed 100 mm/s) 
and with the subject in the 30” anterior oblique position. 
Recordings were made by two operators (R.P. and D.M.). 
Measurements of the left ventricle were made at the tip of 
the mitral valve leaflets, as recommended (14). The other 
variables measured were systolic and diastolic interventric- 
ular septum thickness (IVST), diastolic and systolic left 
ventricular internal diameters (LVIDd and LVIDs) and 
posterior wall thickness (PWT). Left ventricular (LV) vol- 
ume and mass were calculated according to the Devereux 
and Reichek formula (15): 
LV mass = I.Orl[(LVIDp + IVSTp + PWTp)’ - (LVIDP)~] - 13.6, 
where p is the Penn-modified convention for determining 
end-diastolic measurements. Left ventricular mass was then 
converted to a left ventricular mass index by dividing it by 
the body surface area. Fractional shortening (FS), an index 
of left ventricular function, was calculated from end- 
diastolic and end-systolic left ventricular internal dimen- 
sions: 
FS(%) = (LVI - LVIDs)/LVIDd x 100. 
These echocardiographic evaluations were performed by 
two observers and read double blind in random order. 
The reproducibility of the echocardiographic measure- 
ments was tested in a random sample that included 14 of the 
patients participating in the study who were examined twice 
during the first evaluation. The mean differences and stan- 
dard deviations (%) were 3.5 mm (7%) for left ventricular 
internal diameter, 2 mm (12%) for interventricular septum 
thickness, 1.3 mm (9%) for posterior wall thickness and 53 g 
(13%) for left ventricular mass. 
iologic evaluation. Plasma renin activity was measured 
by angiotensin 1 radioimmunoassay (16), and plasma ldo- 
sterone (17) levels were measured after 1 h in the supine 
position and then after 1 h of standing upright. Normal 
values of plasma renin activity and plasma ldosterone levels 
are 0.5 to 2 ng/ml per h and 5 to 15 @IO0 ml, respectively. 
s. Results are expressed asmean values 
+ SD. Mean values were compared with the paired or 
unpaired Student’s t test, as appropriate. Percentages were 
compared with the chi-square test. A p value co.05 was 
considered significant. 
Study group. Of the 5 screened for the study, 
met the criteria for admission (Table 1). The reasons for 
exclusion were a poor quality echocardiogram in seven 
patients, renal artery stenosis in two and renal neoplasm in 
one. Ten of the 44 randomized patients did not participate in
Table 1. Disposition f Patients Screened for Study 
No. 
Patients screened 54 
Not randomized IO 
Poor quality echocardiogram 1 
Renal artery stenosis 2 
Renal neoplasm 1 
Randomized 44 
Final analysis 34 (C18, M16) 
Unexpected control of blood pressure 4 WI 
Adverse effect dropout 5 (C4, Ml) 
Noncompliance I ICI 
C = captopril group; M = minoxidil group. 
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Blood pressure (mm Wgl 
Systolic 
Diastolic 
Heart rate (beatslmin) 
Weight (kg) 
ody surface area (m’) 
Serum creatinine 
(pmollliter) 
Plasma rddosterone 
(ng1100 ml) 
163 z!z 19 16ot 19 NS 
102 f 9 9925 NS 
66% 11 58 2 4 NS 
80.9 z 12.4 76.5 T 11.3 NS 
1.95 + 0.16 1.88 + 0.14 NS 
106.6 t 2 108.4 ? 22.6 NS 
1.4 f 1.8 1.0 2 05 NS 
17.1 f 8.1 14.6 + 6.9 NS 
Values are mean values + SD: NS = not significant. 
y for one of the fd 
(n = 23), major side 
cts in 1 and unexpe 
the first eval~at~~~ a 
before prescription of the trial medicat~0~ in 4. Therefore, 
the final analysis concerned 34 patients, I$ in the capto 
and 16 in the min0xid~~ grou 
The two groups were comparable 
clinical and biologic variables (Table 
examination was not possible at the 
al anal:.sis these patients 
ical and hormonal data. 
isfactory mean blood pressure 
ined in both groups by the end of the trial 
diastohc blood pressures were 
achieved the blood pressure goal in the captopril and minox- 
idil groups was 55.6 and 75.0, respectively (p = NS). The 
mean dose of captopril was 269 -C 54 mglday and the mean 
dose of minoxidil was 20 ? 9 mg. The mean dose of 
furosemide did not differ in the two groups (captopril group 
122 h 40 mg, minoxidil group 110 + 40 mg; p = NS). The 
number of patients given spironolactone was slightly larger 
in the captopril than in the inoxidil group (9 of 18 versus 5 
of 16; p = NS). The mean dose of spirono~actone was 
comparable in both groups (72 ZEZ 22 versus 60 + 22; p = NS). 
The mean weight loss was significant among patients in the 
should be stressed that the patients in both groups had 
severe left ventricular hypertrophy. Their initial echocardio- 
Captopril Minoxidid 
(n = 18) (n = 16) 
- Regimen (daily dose) (rug) 269 -c 54 20%9 
Furosemide tmg) 122 2 40 110 f 40 
Spironolaclone (mg) 72 -+ 22 60 e 22 
SBP (mm Ngt 135 d 19’ 137 r 10’ 
DBP (mm Jig) 89 t to* 87 + 9* 
R (beats/mint 66k8 662 10t 
78.8 + 12.3$ 75.6 c 10.7 
1.92 + 0.16$ 1.87 r 0.14 
reatinine (pmollliter) ttO.3 k 16.1 103.7 t 26.9 
15.8 2 13.7t 4.7 + 3.8t8 
Plasma aldosterone (ng1lOO ml) 26.4 r 18.t 19.8 + 12.7 
“p 4 0.01. tp = 0.01. Sp < 0.05. within group versus control values. 
Bp = 0.01, between group comparison. Values are mean values t SD 
DBP = diastolic blood pressure: H 
wp easurements were 
ever, ~nterventricn~ar 
captopril 
2.5; p = 
~ntervent~~~~~ar septum thickness, posterior wall tht 
left ventricular volume and left ventricular mass index 
improved significantly, end-diastolic left vent~c~~ar i t~r~a~ 
iameter decreased slightly and fractional sho 
contrast, after 6 months’ trea 
ficant variation in these var 
measured and a tendency toward the aggravation f echo- 
graphic indexes was noted. In neither group did t 
tions in the left ventricular mass index correlate 
drop in systolic or diastolic blood pressure or with plasma 
renin activity. Plasma renin activity increased in both 
groups, but as expected, the increase was more marked in 
the captopril group. Plasma aldosterone l vels increased 
groups, but to the same xtent. 
ts. One patient in each group had a 
major adverse side effect: in the captopril group it was 
myocardial infarction and in the minoxidil group it was 
hntense fatigue requiring discontinuation f minoxidil ther- 
apy, followed afew days later by a fatal ischemic stroke. In 
the captopril group, cough resulted in the withdrawal oftwo 
patients from the study and an excessive fall in blood 
in the withdrawal ofanother. 
g (one patient), skin rash (one) and ageusia 
(one); all were resolved by reducing the daily dose of 
captopril. In the minoxidil group, hy ertrichosis was expe- 
rienced by eight patients and ankle ema by seven. These 
side effects were probably due to the treat 
require withdrawal. Gynecomastia appear 
in the minoxidil group who were given 
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, Evolution of Rchocardiographic Left Ventricular Hypertrophy in Resistant Hyfwtensive Patients Given Captopril or 
in a 6 Month Randomized Trial 
Captopril Minoxidil 
Admission 6 Months Admission 6 Months 
(n = 18) (n = 16) p Value* tn = 16) (n = 14) ValPuet VaPue$ VaPueg 
LVlDd (mm) 50.3 + 5.5 48.5 f 6.2 NS 50.2 + 6.2 48.1 + 6.3 NS NS NS 
SF (%I 34.5 + 5.8 31.5 + 3.9 NS 35.3 + 6.4 36.9 + 5.9 NS NS 
IVSTd (mm) 17.4 + 2.7 IS.9 ” 3.5 p c 0.05 15.5 2 2.5 16.1 + 3.0 NS p < 0.01 
PWTd (mm) 14.5 f 2.2 13.4 + 2.2 p < 0.05 14.1 -c 2.0 14.8 + 3.0 NS NS p < 0.01 
LVMI es/m’) 236 + 57 198 f 50 p < 0.001 212 + 31 221 r 51 NS NS p < 0.01 
*Comparison of captopril group at admission and at 6 months: tcomparison of minoxidil group at admission and at 6 months: Scomparison of captopril and 
minoxidil groups at admission: Ocomparison of captopril and minoxidil groups at 6 months. IVSTd = interventricular septum thickness at end-diastole; LVlDd = 
left ventricular internal dimension at end-diastole: LVMI = left ventricular mass index: PWTd = posterior wall thickness at end-diastole; SF = shortening 
fraction. 
spironolactone per day, respectively. Except for the patient 
with myocardial nfarction i  the captopril group, no adverse 
side effects on the heart were observed on electrocardiog- 
raphy. 
seussion 
The main objective of the present study was to evaluate 
left ventricular hypertrophy regression i  a group of patients 
with severe hypertension after 6 months of treatment with 
either minoxidil or captopril. For the first time in humans, as 
far as we know, our readts show that captopril-based triple 
therapy and minoxidil-based triple therapy had opposite 
effects on the heart despite comparable lowering of blood 
pressure. 
Appraisal of the echocardiqyaphic method. We assessed 
the reproducibility of our echocardiographic measurements. 
We found a value of approximately 50g for left ventricular 
mass calculation, which denoted poor reproducibility. Ac- 
cording to Wallerson and Devereux (18) the mean variability 
in left ventricular mass is approximately 25g, and a 50 g 
variation between two examinations must be taken to indi- 
cate left ventricular hypertrophy regression u der treatment. 
Figure 1. Evolution f individual left ventricular mass index values 
(g/m21 in 30 resistant hypertensive patients with left ventricular 
hypertrophy during a randomized 6 month trial with captopril or 
minoxidil. 
CAPTOPRIL GROUP MINOXIDIL GROUP / 
N - 18 N - 14 
On the basis of this criterion our results are within the limits 
of statistical evaluation. These results can be explained by 
four factors: 1) it is difficult to recruit subjects for this type of 
study, because ssential hypertension is not common in 
inpatients who are resistant to two-drug therapy; 2) all of our 
patients were men, many of them overweight, with a mean 
body surface area of about 1.9 m2; 3) in these 
echocardiographic re ordings of good quality 
times difficult o obtain; and 4) in our patients w
high degree of left ventricular hypertrophy, because left 
ventricular mass index exceeded published values. 
Nevertheless, the number of patients tudied, although 
small, was in accordance with the number required (9) and, 
as recommended, we performed ouble-blind readings in 
random order. Analysis of our echocardiographic results 
was statistically in favor of captopril because inthe group of 
patients taking this drug we observed a mean decrease of42 
g in the left ventricular mass index, which exceeds the 7% 
decrease required by Devereux et al. (9). At the time of 
admission to the study, both groups were comparable for all 
left ventricular hypertrophy criteria except interventricular 
septum thickness. During treatment, opposite interventricu- 
lar septum thicknesses were measured ineach group, thus 
increasing the sensitivity of the results. Finally, the trial 
lasted 6 months, asufficiently ong period to appreciate he 
changes in the degree of left ve r hypertrophy 
Mechanisms underlying the t effects of ca 
and minoxidil on left ventricular bypertrophy. Numerous 
studies (6,7,19-261, most dealing with mild hypertension, 
have shown that even short-term antihypertensive treatment 
can induce regression fleft ventricular hypertrophy. Now- 
ever, experiments with rats show that despite comparable 
blood pressure control, such drugs as alpha methyldopa, 
beta-adrenergic blockers, angiotensin-converting enzyme in- 
hibitors and calcium channel blockers (27,28) reduced left 
ventricular hypertrophy, whereas diuretics or direct arterial 
vasodilators alone did not (2,13). Several mechanisms have 
been postulated toexplain these findings. Among the factors 
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July 1 :137-42 
parallel increases in both these variables (2). It was not 
possible to make such a compa~son i  our study, since the 
atients in both groups were given a fixed dose of meto- 
ch inhibits renin release, and varying doses of 
which stimulates the renin-angiotensin system. 
There was kt increase inplasma renin activity in both groups 
due to stimulation ofthe renin-augiotensin system by minox- 
idil, and an increase in renin release due to angiotensin- 
converting enzyme inhibition by captopril. Paradoxically, 
the increase of aldosterone level was higher in the captopril 
group than in the minoxidil group. In the former group the 
doses of diuretics (furos and spironolactone~ andt 
y higher than in the minoxidil 
he resin-angiote~sim system 
might be incomplete with angiote~sin”conve~ing enzyme 
imbibitors (301, a higher volume depletion may exp 
observation. Direct measurement of angiotensin I 
have been necessary to fully understand the changes in the 
level of renin-angiotensin-aldosterone system activation i  
the two groups. 
failed to induce this regresston. 
were unable to answer tbe i 
Wh r the drug-induced regression 
ertrophy is necessary an 
the present findings concern a special sub- 
group of patients, and cannot be extrapolated to all subjects 
with essential hypertension cardiac variables are 
altered to a lesser extent (36 over, it has also been 
pointed out that regression 
might be associated with persisteat nat 
are potentially a~bythmogen~c (37). 
We thank Carmen Kreft and Paolo Sassano for their helpful assistance during 
this work. 
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